Board members at this company
As a member of Board of Directors at REGENERX BIOPHARMACEUTICALS,
Allan Goldstein, Ph.D. made $166,785 in total compensation. Of this total
$0 was received as fees earned or paid in cash,
$0 was received as non-stock incentive plan compensation,
$0 was received as change in pension value and nonqualified deferred compensation earnings,
$76,785 was received as options,
$0 was awarded as stock and
$90,000 came from other types of compensation. This information is according to proxy statements filed for the 2020 fiscal year.
Fiscal Year Ended in 2020
The chart on this page features a breakdown of the total annual pay for Allan Goldstein, Ph.D. at REGENERX BIOPHARMACEUTICALS as reported in their proxy statements.
Fees Earned or Paid in Cash: This is the amount of fixed retainers and meeting fees and paid in the form of cash.
Stock Awards: Compensation paid in the form of company equity that is structured as restricted stock.
Option Awards: Compensation paid in the form of company equity that is structured as stock options.
Non-Stock Incentive Plan Compensation: Cash compensation earned for the achievement of predefined objectives.
Change in Pension Value and Nonqualified Deferred Compensation Earnings: The difference between such compensation between the prior year and the current year.
All Other Compensation: Compensation that is paid in the form of perquisites, such as expense reimbursement.
Total Named Director Compensation: The sum of all dollar values above.
Other Board members at this Company
Allan Goldstein, Ph.D.
None-Stock Inc.Plan Comp
Change in Pen.& Non-Q DEF.Comp
Browse Board of Directors By First Name
Browse Companies by Company Name
This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However, for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.